The present application discloses methods of making anti-hepsin antibodies, anti-hepsin antibodies, methods of screening the activity of anti-hepsin antibodies, pharmaceutical compositions of anti-hepsin antibodies, kits containing anti-hepsin antibodies, and methods of using anti-hepsin antibodies to diagnose a cancer.

The present application discloses methods of making anti-hepsin antibodies, anti-hepsin antibodies, methods of screening the activity of anti-hepsin antibodies, pharmaceutical compositions of anti-hepsin antibodies, kits containing anti-hepsin antibodies, and methods of using anti-hepsin antibodies to diagnose a cancer.

Methods of lowering LDL cholesterol in a pediatric subject having a cholesterol-related disorder, e.g., heterozygous familial hypercholesterolemia (HeFH), by administering a PCSK9 inhibitor are provided.

Methods of lowering LDL cholesterol in a pediatric subject having a cholesterol-related disorder, e.g., heterozygous familial hypercholesterolemia (HeFH), by administering a PCSK9 inhibitor are provided.

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

Provided is application of chimeric antigen receptor (CAR)-modified T (CART) cells in preparing drugs for cancer treatment, the CART cells contain an artificially-introduced costimulatory signal transduction domain, and the CART cell does not contain an artificially-introduced first signal transduction domain.

Disclosed herein are compositions and methods for the treatment of one or more progressive lung diseases, which may include, but are not limited to, chronic obstructive pulmonary disease (COPD), emphysema, and AAT deficient lung disease. The compositions useful for the disclosed methods may include an an antigen binding protein such as an anti-CELA1 antibody, an anti-CELA1 scFv, or an anti-CELA1 antisense nucleotide (ASO), which may be administered in an amount sufficient to treat one or more of the aforementioned disease states.

Disclosed herein are compositions and methods for the treatment of one or more progressive lung diseases, which may include, but are not limited to, chronic obstructive pulmonary disease (COPD), emphysema, and AAT deficient lung disease. The compositions useful for the disclosed methods may include an an antigen binding protein such as an anti-CELA1 antibody, an anti-CELA1 scFv, or an anti-CELA1 antisense nucleotide (ASO), which may be administered in an amount sufficient to treat one or more of the aforementioned disease states.

Monoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.